Determination of symptoms and symptom clusters in breast cancer patients receiving adjuvant chemotherapy treatment

Yıl 2024, Cilt: 10 Sayı: 3, 225 - 235, 31.12.2024

Berna Kurt

https://doi.org/10.30569/adiyamansaglik.1481290

Öz

Aim: To examine the symptom clusters in breast cancer patients receiving adjuvant chemotherapy treatment.
Materials and Methods: This descriptive study examined 128 female patients between February 2022-August 2023 using Memorial Symptom Assessment Scale, and EORTC QLQ-C30 Scale.
Results: In cluster analysis, 23 symptoms with a prevalence of >25% were selected, and six clusters were identified. First cluster is nausea, loss of appetite, and fatigue/loss of energy; second cluster is taste change, dry mouth, mucositis, vomiting, weight loss, and diarrhea; third cluster is worrying, feeling nervous, drowsy, and difficulty sleeping; fourth cluster is feeling bloated, shortness of breath, and difficulty swallowing; fifth cluster is alopecia, not look like herself, feeling irritable, sad; and last cluster includes problems with sexual interest, activity, pain, and sweating.
Conclusion: It may be recommended to plan and evaluate applications or interventions in breast cancer patients receiving adjuvant chemotherapy treatment for the six symptom clusters identified.

Anahtar Kelimeler

Breast Cancer, Chemotherapy, Nursing, Symptom Cluster

Etik Beyan

This study, approval was obtained from the Hacettepe University Non-Interventional Clinical Research Ethics Committee (Number GO 21/1287). All interventions were carried out following institutional ethical standards and the national research committee, including the 1964 Declaration of Helsinki and subsequent amendments. Furthermore, the study's participants provided both verbal and written permissions.

Destekleyen Kurum

None.

Teşekkür

The author would like to acknowledge all patients who participated in this study.

Adjuvan kemoterapi tedavisi alan meme kanserli hastalarda görülen semptomlar ve semptom kümelerinin belirlenmesi

Öz

Amaç: Adjuvan kemoterapi tedavisi alan meme kanserli hastalarda görülen semptom kümelerini incelemektir.
Gereç ve Yöntem: Şubat 2022-Ağustos 2023 tarihleri arasında 128 kadın hasta ile gerçekleştirilen tanımlayıcı tipteki bu çalışmanın verileri Memorial Semptom Değerlendirme Ölçeği (MSDÖ) ve EORTC QLQ-C30 Yaşam Kalitesi Ölçeği kullanılarak toplandı.
Bulgular: Kümeleme analizinde >%25 prevalansı olan 23 semptom seçildi ve altı semptom kümesi belirlendi. Birinci küme; bulantı, iştahsızlık ve halsizlik/enerji kaybı, ikinci küme; yiyeceklerin tadını almada değişiklik, ağız kuruluğu, ağız yaraları, kusma, kilo kaybı ve ishal, üçüncü küme; endişelenme, kendini sinirli hissetme, uyumada zorluk ve kendini uykulu ya da sersemlemiş gibi hissetme, dördüncü küme; şişkinlik hissi, nefes darlığı ve yutma güçlüğü, beşinci küme; saç dökülmesi, kendine benzememe, hassas olma ve kendini üzgün hissetme iken altıncı kümede; cinsel istek veya aktivite ile ilgili sorunlar, ağrı ve terleme yer almaktadır.
Sonuç: Meme kanserli hastalardaki uygulamaların ya da girişimlerin belirlenen altı semptom kümesine yönelik planlanması ve değerlendirilmesi önerilebilir.

Anahtar Kelimeler

Hemşirelik, Kemoterapi, Meme Kanseri, Semptom Kümesi

Etik Beyan

This study, approval was obtained from the Hacettepe University Non-Interventional Clinical Research Ethics Committee (Number GO 21/1287). All interventions were carried out following institutional ethical standards and the national research committee, including the 1964 Declaration of Helsinki and subsequent amendments. Furthermore, the study's participants provided both verbal and written permissions.

Destekleyen Kurum

None.

Teşekkür

TThe author would like to acknowledge all patients who participated in this study.

Kaynakça

• International Agency for Research on Cancer. GLOBOCAN 2020: Estimated cancer incidence, mortality and prevalence worldwide in 2020. Erişim Adresi: https://gco.iarc.fr/tomorrow/en/dataviz/isotype Erişim Tarihi: 05.08.2023
• Sert Pİ, Küçükkılınç ZTT. Meme Kanseri Tedavisindeki Güncel Yaklaşımlar. Hacettepe University Journal of the Faculty of Pharmacy. 2022;42(1):46-59.
• Pekmezci H, Köse BG, Akbal Y, et al. Kemoterapi alan kanser hastalarının semptom yönetiminde tamamlayıcı terapi kullanımları. Journal of Health Academics/Sağlık Akademisyenleri Dergisi. 2022;9(3).
• Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med care. 2011; 39(10):1118-1130.
• Dong ST, Butow PN, Costa DS, et al. Symptom clusters in patients with advanced cancer: a systematic review of observational studies. J Pain Symptom Manage. 2014;48(3):411‐450.
• Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients. Cancer. 2000;89(7):1634-1646.
• Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30(9):1326-36.
• Yıldırım Y, Tokem Y, Bozkurt N, et al. Reliability and validity of the Turkish version of the memorial symptom assessment scale in cancer patients. Asian Pacific Journal of Cancer Prevention. 2011;12(12):3389-3396.
• Fayers P, Bottomley A. E. O. R. T. C., & EORTC Quality of Life Group. Quality of life research within the EORTC—the EORTC QLQ-C30. Eur J Cancer. 2002; 38: 125-133.
• Guzelant A, Goksel T, Ozkok S, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30. Eur J Cancer Care. 2004; 13: 135-144.
• Walsh D, Rybicki L. Symptom Clustering In Advanced Cancer. Support Care Cancer.2006;14:831–836.
• Kim HJ, McGuire DB, Tulman L, et al. Symptom Clusters Concept Analysis and Clinical Implications for Cancer Nursing. Cancer Nurs. 2005;28 (4):270-282
• Kim H, Barsevick A, Tulman L, et al. Treatment-related symptom clusters in breast cancer: a secondary analysis. J Pain Symptom Manage. 2008;36:468-479.
• Molassiotis A, Farrell C, Bourne K, et al. An exploratory study to clarify the cluster of symptoms predictive of chemotherapy-related nausea using random forest modeling. J Pain Symptom Manage. 2012;44: 692e703.
• Albusoul RM, Berger AM, Gay CL, et al. Symptom clusters change over time in women receiving adjuvant chemotherapy for breast cancer. J Pain Symptom Manage. 2017;53(5), 880-886.
• Alkathiri AM, Albothi GK. Symptom cluster and severity among women with breast cancer undergoing chemotherapy in Saudi Arabia. J Med Med Sci. 2015;6(2):40-46.
• Matthews EE, Schmiege SJ, Cook PF, et al. Breast cancer and symptom clusters during radiotherapy. Cancer Nurs. 2012;35(2):1-11.
• Starkweather A, Kelly DL, Thacker L, et al. Relationships among psychoneurological symptoms and levels of C-reactive protein over 2 years in women with early-stage breast cancer. Support Care Cancer. 2017;25(1):167-176.
• Roiland RA, Heidrich SM. Symptom clusters and quality of life in older adult breast cancer survivors. Oncol Nurs Forum. 2011; 38(6): 672-680.
• Browall M, Brandberg Y, Nasic S, et al. A prospective exploration of symptom burden clusters in women with breast cancer during chemotherapy treatment. Support Care Cancer. 2017; 25(5): 1423-1429.
• Li H, Sereika SM, Marsland AL, et al. Symptom clusters in women with breast cancer during the first 18 months of adjuvant therapy. J Pain Symptom Manage. 2020;59(2):233-241.
• Mazor M, Cataldo JK, Lee K, et al. Differences in symptom clusters before and twelve months after breast cancer surgery. Eur J Oncol Nurs. 2018; 32:63-72.
• Chongkham-ang S, Wonghongkul T, Panuthai S, et al. Symptom experience and symptom clusters of Thai women with breast cancer receiving chemotherapy. Pacific Rim Int J Nurs Res. 2018;22(1):43-57
• Hsu HT, Lin KC, Wu LM. Symptom cluster trajectories during chemotherapy in breast cancer outpatients. J Pain Symptom Manage. 2017;53(6):1017-1025.
• Chow S, Wan BA, Pidduck W. Symptom clusters in patients with breast cancer receiving radiation therapy. Eur J Oncol Nurs. 2019;42:14-20.
• Ward Sullivan C, Leutwyler H, Dunn LB. Stability of symptom clusters in patients with breast cancer receiving chemotherapy. J Pain Symptom Manage. 2018;55(1):39-55.
• Thornton LM, Andersen BL, Blakely WP. The pain, depression, and fatigue symptom cluster in advanced breast cancer: covariation with the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. Health Psychol. 2010;29(3):333–337
• Kim HJ. Common biological pathways underlying the psychoneurological symptom cluster in cancer patients. Cancer Nurs.2012;35(6):1–20
• Phligbua W, Pongthavorakamol K, Knobf TM, et al. Symptom clusters and quality of life in women with breast cancer receiving adjuvant chemotherapy. Pacific Rim Int J Nurs Res. 2013;17(3):249-267.
• Li H, Sereika SM, Marsland AL, et al. Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy. J Clin Nurs. 2019; 28(23–24):4560-4571.
• Can G, Durna Z, Aydiner A, et al. Sistemik tedavi alan meme kanserli kadınlarda cinsel fonksiyonların değerlendirilmesi. Androloji Bülteni. 2005;22:268-271.
• Krebs L. What Should I Say? Talking with Patients About Sexuality Issues. Clin J Oncol Nurs. 2006;10(3):313-315.
• Broeckel JA, Thors CL, Jacobsen PB, et al: Sexual functioning in long-term breast cancer survivors treated with adjuvant chemotherapy. Breast Cancer Res Treatment. 2002;75:241-248.
• Çam O, Gümüş AB. Meme Kanserli Kadınlar için Duygusal Destek Odaklı Hemşirelik Girişimleri. C.Ü. Hemşirelik Yüksekokulu Dergisi. 2006;10(3):52-60.